Screening and Management of High-risk Populations of Stroke in Dehui City (SAMHPSDC)

August 31, 2021 updated by: Yi Yang
This epidemiological survey is to analyze the prevalence rate of stroke and exposure rate of risk factors in sampling population aged 40 years and over (born before December 31,1975) in Dehui City, to provide scientific basis for pertinent prevention and control of stroke in Jilin Province, and to provide valuable data for the high-risk groups to carry out regular follow-up and standardized management.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

4100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Jilin
      • Changchun, Jilin, China, 130000
        • First Hospital of Jilin University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Target population aged 40 years and over (born before December 31,1975) was selected from Dehui City by means of group sampling.

Description

Inclusion Criteria:

  • Aged 40 years and over in Dehui City
  • Willing to participate in the study and follow-up visits
  • Signed an informed consent

Exclusion Criteria:

  • Life expectancy<3 years
  • Unwilling to participate in the study and follow-up visits
  • Living away from Dehui City over 6 months
  • Unable to cooperate with examination and questionnaire due to mental disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Low-risk Group
Low-risk Group is defined as the population with <3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but without chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
Other: Advice according to primary prevention guidelines on stroke of China
Mediate-risk Group
Mediate-risk Group is defined as the population with <3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), but meanwhile suffer from chronic disease (hypertension, diabetic mellitus, atrial fibrillation or valvular heart disease).
Other: Advice according to primary prevention guidelines on stroke of China
High-risk Group
High-risk Group is defined as the population with ≥3 risk factors (hypertension, dyslipidemia or dyslipoproteinemia, diabetic mellitus, atrial fibrillation or valvular heart disease, smoking, lack of exercise or light manual labor, overweight or obesity and family history of stroke), or population with history of stroke or/and transient ischemic attack.
Other: Advice according to primary prevention guidelines on stroke of China

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence rate of stroke
Time Frame: 4 months
The proportion of stroke in the general population.
4 months
Prevalence rate of hypertension
Time Frame: 4 months
The proportion of hypertension in the general population.
4 months
Prevalence rate of diabetes mellitus
Time Frame: 4 months
The proportion of diabetes mellitus in the general population.
4 months
Prevalence rate of dyslipidemia
Time Frame: 4 months
The proportion of dyslipidemia in the general population.
4 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yi Yang

Collaborators

Dehui People's Hospital

Investigators

  • Study Chair: Yi Yang, M.D. Ph.D., The First Hospital of Jilin University
  • Study Director: Ying-Qi Xing, M.D. Ph.D., The First Hospital of Jilin University
  • Study Director: Zhen-Ni Guo, M.D., The First Hospital of Jilin University
  • Principal Investigator: Fu-Liang Zhang, M.D., The First Hospital of Jilin University
  • Principal Investigator: Hao-Yuan Liu, M.D., The First Hospital of Jilin University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2016

Primary Completion (Actual)

March 31, 2016

Study Completion (Actual)

March 31, 2017

Study Registration Dates

First Submitted

August 30, 2021

First Submitted That Met QC Criteria

August 31, 2021

First Posted (Actual)

September 9, 2021

Study Record Updates

Last Update Posted (Actual)

September 9, 2021

Last Update Submitted That Met QC Criteria

August 31, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SMDC

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Advice according to primary prevention guidelines on stroke of China

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe